Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19
Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight and lowers the price target from $20 to $19.
Read original at benzingaStocks · News reference
8-K filing — Immix Biopharma, Inc. (IMMX)
Filed: 2026-07-20 AccNo: 0001493152-26-033829 Size: 197 KB Item 8.01: Other Events
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 20, 2026, 10:05 AM
- Checked
- Jul 20, 2026, 10:05 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $20 to $25.
Read original at benzingaNeedham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21
Needham analyst Gil Blum initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $21.
Read original at benzingaImmix Biopharma shares are trading lower. A report suggested that a fugitive worked as an executive for the company.
Read original at benzinga